Aktieanalys

ChromoGenics Q4 2023: Weak topline and higher costs, but the order pipeline looks good - Redeye

{newsItem.title}

Redeye Publicerad: 08 Mar 2024 09:23

Redeye comments on ChromoGenics Q4 2023 report.

Länk till analysen i sin helhet: https://www.redeye.se/research/969916/chromogenics-q4-2023-weak-topline-and-higher-costs-but-the-order-pipeline-looks-good?utm_source=finwire&utm_medium=RSS

Nyheter om ChromoGenics

Läses av andra just nu

Om aktien ChromoGenics

Senaste nytt